Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914819 | Molecular Oncology | 2015 | 11 Pages |
Abstract
This study provides an assessment of tumor cMET gene copy number changes and protein overexpression incidence in a cohort of Chinese GC patients. To our knowledge, this is the first study to demonstrate anti-tumor efficacy in a panel of cMET-dysregulated gastric cancer PDX models, using a novel selective cMET-inhibitor (volitinib). Thus, the translational science presented here provides strong rationale for the investigation of volitinib as a therapeutic option for patients with GC tumors harboring amplified cMET.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul R. Gavine, Yongxin Ren, Lu Han, Jing Lv, Shiming Fan, Wei Zhang, Wen Xu, Yuan Jie Liu, Tianwei Zhang, Haihua Fu, Yongjuan Yu, Huiying Wang, Shirlian Xu, Feng Zhou, Xinying Su, XiaoLu Yin, Liang Xie, Linfang Wang, Q. May Wang,